Summary Dova Pharmaceuticals Inc (Dova), formerly PBM AKX Holdings LLC, is a clinical-stage pharmaceutical company that acquires, develops and commercializes therapies for the treatment of orphan diseases.The company’s lead candidate, Avatrombopag (DOPTELET), a novel, oral thrombopoietin receptor agonist, is approved byFDA for the treatment of thrombocytopenia in patients suffering from chronic liver disease.
Its product candidate stimulates platelet production and limits platelet transfusion-associated risks including infections, immune reactions and refractories.The company develops therapies for the acute treatment and chronic treatment of thrombocytopenia and cancer.
Dova is headquartered in Durham, North Carolina, the US.
Dova Pharmaceuticals Inc (DOVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Iron Deficiency Anemia - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2019, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape. Anemia is a condition...
290 pages •
By Asia Market Information & Development Company
• Oct 2019
China’s demand for Blood Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Toll Like Receptor 4 - Pipeline Review, H2 2019 Summary Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent...
Reflux Esophagitis - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2019, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape. When the liquid content of the stomach...
145 pages •
By Asia Market Information & Development Company
• Oct 2019
This study focuses on China’s Blood Disease Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...
Asia Pacific Prenatal and Newborn Genetic Testing Market to 2027 – Regional Analysis and Forecasts by Type, Disease Indication, Technology, and End User The Asia Pacific prenatal and newborn genetic testing market is expected to reach US$ 2,570.37 Mn in 2027 from US$ 878.28 in 2018. The market is estimated to grow with a CAGR of 12.8% from...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.